Tag:
selumetinib
Latest Headlines
Latest Headlines
UPDATED: ASCO abstracts reveal added appeal for key cancer drug prospects
The avalanche of ASCO abstracts last night triggered a flurry of news reports about the most notable new data on experimental therapies to be revealed ahead of next month's big meeting in Chicago.
AstraZeneca flunks Ph2 lung cancer trial with drug from Array BioPharma
Array BioPharma ( $ARRY ) delivered some bad news this morning about one of its experimental cancer drugs. AstraZeneca--which has licensed Array's the drug, selumetinib--came up short in in a mid-stage
